Media.Player

Technology for Engineering Antibodies with Infinite Affinity for their Antigen

Technology Benefits

Synthetic tag to replace avidin-biotin No competition from endogenous ligands No dissociation after capture Humanized format

Technology Application

Targeted medical imaging Targeted medical therapies (e.g. cancer therapeutics)

Detailed Technology Description

Over a million new cases of cancer will be diagnosed this year in the United States. While surgery and chemotherapeutic drugs can often provide definitive treatment of cancer, the eradication of metastases is crucial to the cure of more advanced disease. Despite the expenditure of large amounts of resources, better treatments for cancer are sorely needed. Researchers at the University of California, Davis have developed a technology for engineering antibodies to bind irreversibly, with high affinity and specificity, to their receptor. This technology provides an alternative to using combinatorial selection, directed evolution, or other methods for improving the affinity of antibodies to ligands. The specific requirements for an antibody with infinite affinity are: 1) When the antibody and ligand are apart, their complementary reactive groups do not react significantly with other molecules in the medium; 2) When the ligand binds to the antibody, the effective concentrations of their complementary reactive groups are sharply elevated, and a covalent link is formed and; 3) The covalently linked antibody/ligand complex cannot dissociate.

Supplementary Information

Patent Number: US7118745B1
Application Number: US2000671953A
Inventor: Meares, Claude | Chmura, Albert
Priority Date: 27 Sep 1999
Priority Number: US7118745B1
Application Date: 27 Sep 2000
Publication Date: 10 Oct 2006
IPC Current: A61K003940 | A61K0039395 | C07K001600
US Class: 4241791 | 42400111 | 42400153 | 42400165 | 42400169 | 5303871 | 5303873 | 5303881 | 5303888 | 5303911 | 424001149
Assignee Applicant: The Regents of the University of California
Title: Engineering antibodies that bind irreversibly
Usefulness: Engineering antibodies that bind irreversibly
Summary: The invention provides engineered antibodies and chelates that are useful as analytical agents and in clinical diagnosis, as well as in the treatment of disease, particularly cancer.
Novelty: Nucleic acid encoding a mutant antibody comprising a reactive site that specifically binds to a metal chelate useful as analytical agents and in clinical diagnosis, as well as in the treatment of disease, particularly cancer

Industry

Disease Diagnostic/Treatment

Sub Category

Cancer/Tumor

Application No.

7820787

Others

Tech ID/UC Case

25888/2001-433-0

Related Cases

2001-433-0

*Abstract

Researchers at the University of California, Davis have developed a unique technology for engineering antibodies that bind irreversibly to their receptor.

*IP Issue Date

Oct 26, 2010

*Principal Investigator

Name: Todd Corneillie

Department:

Name: Claude Meares

Department:

Country/Region

USA